Endo International plc (NASDAQ:ENDP) Sees Large Decline in Short Interest

Endo International plc (NASDAQ:ENDPGet Rating) (TSE:ENL) was the recipient of a large decrease in short interest in July. As of July 31st, there was short interest totalling 36,590,000 shares, a decrease of 11.7% from the July 15th total of 41,450,000 shares. Approximately 18.2% of the company’s shares are short sold. Based on an average daily trading volume, of 48,210,000 shares, the days-to-cover ratio is presently 0.8 days.

Institutional Trading of Endo International

Institutional investors and hedge funds have recently modified their holdings of the stock. Nisa Investment Advisors LLC grew its holdings in Endo International by 500.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 18,000 shares of the company’s stock valued at $57,000 after purchasing an additional 15,000 shares during the period. New York State Common Retirement Fund boosted its position in shares of Endo International by 21.1% during the fourth quarter. New York State Common Retirement Fund now owns 162,817 shares of the company’s stock worth $612,000 after purchasing an additional 28,352 shares in the last quarter. Yousif Capital Management LLC acquired a new position in shares of Endo International in the 4th quarter valued at $814,000. Russell Investments Group Ltd. grew its holdings in shares of Endo International by 303.0% in the 2nd quarter. Russell Investments Group Ltd. now owns 1,137,391 shares of the company’s stock valued at $527,000 after buying an additional 855,145 shares during the period. Finally, Mitsubishi UFJ Trust & Banking Corp increased its position in shares of Endo International by 34.0% in the 1st quarter. Mitsubishi UFJ Trust & Banking Corp now owns 438,499 shares of the company’s stock valued at $1,013,000 after buying an additional 111,380 shares in the last quarter. 80.39% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on ENDP shares. Piper Sandler cut Endo International from a “neutral” rating to an “underweight” rating and lowered their target price for the company from $3.00 to $1.00 in a research note on Friday, May 6th. BMO Capital Markets dropped their price objective on Endo International from $4.00 to $2.00 in a report on Monday, May 9th. Barclays reduced their target price on shares of Endo International from $2.00 to $1.00 in a research note on Monday, May 9th. Finally, StockNews.com assumed coverage on shares of Endo International in a research note on Friday, July 29th. They set a “hold” rating for the company. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, Endo International presently has a consensus rating of “Hold” and a consensus price target of $2.50.

Endo International Stock Down 23.3 %

NASDAQ ENDP traded down $0.09 on Wednesday, reaching $0.28. The company had a trading volume of 233,920,272 shares, compared to its average volume of 25,605,367. Endo International has a 52 week low of $0.28 and a 52 week high of $7.07. The stock’s 50 day moving average is $0.46 and its 200-day moving average is $1.55. The stock has a market cap of $66.76 million, a price-to-earnings ratio of -0.03 and a beta of 1.15.

About Endo International

(Get Rating)

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology.

Read More

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.